BMO Capital Believes Eli Lilly & Co (LLY) Won’t Stop Here


BMO Capital analyst Alex Arfaei maintained a Buy rating on Eli Lilly & Co (LLY) yesterday and set a price target of $124. The company’s shares closed yesterday at $114.34, close to its 52-week high of $119.84.

According to TipRanks.com, Arfaei is a 5-star analyst with an average return of 8.6% and a 72.1% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Elanco Animal Health Inc, Merck & Company, and Bristol Myers.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eli Lilly & Co with a $123.45 average price target.

See today’s analyst top recommended stocks >>

Based on Eli Lilly & Co’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $1.15 billion. In comparison, last year the company earned revenue of $5.66 billion and had a net profit of $556 million.

Based on the recent corporate insider activity of 134 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts